Drug intelligence / Profile preview

iCELL-OA

Development stage: Preclinical
Lead developer: iCELL Biotechnology
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intraarticular

Overview

iCELL-OA is an adipose-derived mesenchymal stem cell (Adipose MSC) therapy developed by iCELL Biotechnology for the treatment of osteoarthritis. Adipose-derived MSCs are multipotent cells harvested from fat tissue that possess significant immunomodulatory and regenerative potential. When administered to the osteoarthritic joint, these cells are intended to reduce synovial inflammation and promote the repair of damaged articular cartilage by secreting various cytokines and growth factors (paracrine signaling) and potentially differentiating into chondrocytes. The therapy is currently in the preclinical stage of development, focusing on alleviating joint pain and slowing disease progression.

Other names: Adipose-derived Mesenchymal Stem CellsAdipose MSCs

Beyond the preview

Go deeper on iCELL-OA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on iCELL-OA.

Explore the full profile